Why does ALK-positive lung cancer spread to the brain?

Question

Hi doctor,

I am writing this on behalf of my younger brother, who is 38 and has never smoked in his life, not even passive smoking, really, because he grew up in a very strict household. He was diagnosed with lung cancer eight months ago, and we were managing fine with treatment, but last week his MRI showed three new brain metastases, the largest being 1.4 cm in the right frontal lobe. He is already on Lorlatinib for his ALK-positive lung cancer, and we thought it was supposed to cross the blood-brain barrier and protect against this.

Why did his lung cancer spread to the brain at age 38, as a non-smoker, even while he was on a drug specifically chosen to prevent this?

His neurologist and oncologist had a joint meeting and are now recommending stereotactic radiosurgery for the brain lesions while continuing the Lorlatinib. He has been having headaches for three weeks, which we all assumed were stress and anxiety. He also started forgetting small things and had one episode where he could not remember the word for common objects for a few minutes, which really scared the whole family. His performance status has dropped noticeably in the last month.

How aggressive can we be with treating the brain mets without causing more damage to his brain function?

Please help.

Thank you.

Answer 1

Hi,

Welcome to icliniq.com.

I have read your query and understand your concern. I can understand how frightening this must be for you and your family.

When someone is already on treatment and a new finding like brain metastasis appears, it can feel very discouraging and confusing. Many families expect that medicines like Lorlatinib will completely prevent spread to the brain, so it is natural to question why this has happened.

Lorlatinib is one of the targeted drugs used for ALK-positive lung cancer, and it is specifically designed to reach the brain by crossing the blood-brain barrier. In many patients, it does not control or delay brain involvement. However, cancer cells can sometimes adapt over time and develop resistance to treatment. Because of that, a few new lesions can still appear in the brain even while the medication continues to control the disease in other parts of the body. This situation is unfortunately something doctors do see in practice, and it does not mean the earlier treatment choice was wrong.

In ALK (anaplastic lymphoma kinase)-positive lung cancer, the brain is a relatively common site where metastases can appear during the course of the disease. When only a small number of lesions are found, doctors often recommend treating those spots directly while continuing the targeted therapy that is helping control the rest of the cancer. This is the reason your doctors suggested stereotactic radiosurgery while continuing lorlatinib.

Stereotactic radiosurgery is a very focused form of radiation that targets only the tumor areas with minimal exposure to surrounding brain tissue. Because it is precise, it is generally preferred when there are only a few lesions, like in your brother’s case. Compared with whole-brain radiation, this approach is usually associated with a lower risk of long-term effects on memory and overall brain function. The symptoms you described, such as headaches, brief difficulty finding words, or short episodes of confusion, can occur when lesions affect areas of the brain responsible for thinking or language, especially the frontal lobe. Once the lesions are treated and swelling reduces, these symptoms may improve in some patients.

In many cases, doctors can treat brain metastases quite aggressively while still protecting brain function, especially when the number of lesions is small and modern techniques like stereotactic radiosurgery are used. Continuing the targeted therapy alongside this treatment is a common strategy to control the disease both inside and outside the brain.

Hope I have addressed all of your queries and concerns.

Do follow up whenever needed.

Best wishes.